The findings complement the most recent findings from observational research and need to be considered within the context of other available alternative of diabetes therapy which have shown a lower risk of HF compared to DPP-4 inhibitors (i.e. SGLT2 inhibitors) [25]. This evidence concerns the gene SLC5A2 and hydrops fetalis.